When: Close below $27.30 on volume >50M (10 EMA break)

Then: EXIT remaining position - short-term trend failure

When: Close below $25.22 with rising volume (50 SMA cluster break)

Then: EXIT remaining position - structural failure

When: >$3B impairment announcement or dividend language softens/cut chatter emerges

Then: EXIT or DOWNGRADE to Sell

TRIM to 50-70% of model weight; retain core exposure with defined stop at 200 SMA zone (~25.22); do not initiate new positions; preserve dividend carry and optionality for Q3 confirmation

• 2025 calendar year FCF was 9.08 billion covering 9.77 billion in dividends at 0.93x, but TTM FCF is 12.49 billion yielding 1.28x coverage, with the gap driven by a 3.3 billion Q2 2025 tax payment
• Q2 2026 impairments of 4.33 billion and Q4 2025 impairments of 4.47 billion (acquired IPR&D and Seagen intangibles) compress TTM EPS to 0.76 versus normalized forward earnings; trailing P/E of 37.59 is misleading due to non-cash write-downs
• Forward P/E of 9.87 reflects normalized earnings power (~2.90 forward EPS), not inflated multiples
• Technical setup is extended but trend remains intact: RSI at 73.95, MACD histogram compressed from 0.254 to 0.153, 50 SMA sits 5 cents below 200 SMA (golden cross unconfirmed), but 10 EMA at 27.57 has flipped to support
• Price made higher highs and higher lows from July 31 to August 25; volume expanding on breakout; base from 23.21 in late June
• Zero Reddit mentions is neutral to mildly positive (no crowded positioning or meme dynamics to unwind)
• Macro backdrop favors carry: Fed on hold with 86% probability of zero cuts in 2026, recession probability at 8%, soft landing environment
• 6.15% dividend yield from low-beta 0.28 name is attractive carry in current environment; patent cliff risk is 12-18 months out and largely priced in
• Aggressive full liquidation requires perfect double execution: selling now and reloading at 25.50-26.00; forfeits 1.50 dollars per share in annual dividend income plus tax friction
• Defined drawdown tolerance of 25-30% on retained position; stop zone at 200 SMA around 25.22

→ vs aggressive: Aggressive case cherry-picks 2025 FCF of 9.08 billion to show 0.93x dividend coverage when TTM is 12.49 billion (1.28x); Q2 2025 absorbed a 3.3 billion tax payment and working capital seasonality explains quarterly swings (negative 1.2B Q2, positive 4.5B Q4, positive 2.18B Q1 2026), not structural breakdown

→ vs aggressive: Calling for dividend cut as base case is overreach; prerequisites for a 15-20% re-rating event are not in place

→ vs aggressive: Forward P/E of 9.87 is not a fiction; it reflects normalized earnings stripping out non-cash impairments; calling it dishonest ignores the fundamental purpose of forward multiples

→ vs aggressive: Reading distribution from single RSI tick and fading MACD histogram ignores the broader pattern: higher highs/lows, expanding volume on breakout, 10 EMA support, rising VWMA

→ vs aggressive: Short-term overbought is not the same as a top, especially in a stock that completed a base from 23.21 in late June

→ vs aggressive: Zero Reddit mentions is neutral to mildly positive, not bearish; it means no crowded positioning or meme-driven unwind risk

→ vs aggressive: Full liquidation and reload at 25.50-26.00 is a market-timing trade requiring two perfect executions, not risk management; forfeits 1.50 dollars per share in annual income and incurs tax friction

→ vs aggressive: Patent cliff risk is 12-18 months out, well-flagged, and largely priced into the valuation discount; it is not a sudden near-term catalyst

→ vs neutral: The trader's plan to trim to 50-70% with a defined stop is endorsed as the conservative path

SELL (Trim to 50-55%, no new capital, trailing stop at 27.30)

• Trailing twelve months FCF coverage is 1.28x (12.49B FCF / 9.77B dividends), adequate but not robust
• Technical breakout is intact with higher highs and higher lows for 8 straight sessions; 10 EMA support at 27.57
• Current price of 28.57 is 23% above June lows of 23.21, materially changing risk-reward from base-building phase
• RSI at 74 and MACD histogram compression (0.254 to 0.153) indicate short-term caution but not trend reversal
• Eliquis patent cliff risk (12-18 months out) could shave ~1.3B annually from 10% revenue decline
• Normalized earnings power materially higher than trailing 0.76, suggesting P/E is lower than 37.59x
• Exit signal: close below 27.30 on volume; re-entry signal: reclaim 28.93 on volume above 50M
• Dividend carry of 6.15% ($1.50/share annually) justifies holding partial position but not full weight
• Aggressive analyst timing call on dividend cut is low probability over next 6-12 months given management guidance
• Conservative analyst retail mention analysis is neutral at best, not a genuine positive

→ vs aggressive: Calling for dividend cut as base case when TTM coverage is 1.28x and management just raised guidance midpoint is front-running an unhinted event; the 1.28x coverage ratio smooths through Q2 2025 working capital distortion and the impairment noise cuts both ways on normalized earnings

→ vs conservative: Defending full position after 23% run from lows with RSI at 74 and price at upper Bollinger band ignores materially different risk-reward at current entry versus bottom of base; also underweights structural risk envelope from patent cliff which is a moving target, not a fully priced-in known quantity